Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY: OSTX )

2.950 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,174
Open 2.950
Bid (Size) 3.150 (18)
Ask (Size) 3.180 (13)
Prev. Close 2.950
Today's Range 2.950 - 2.950
52wk Range 1.580 - 7.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?
OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls. 
Via Benzinga
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
From OS Therapies, Inc.
Via Business Wire

Performance

YTD
-29.43%
-29.43%
1 Month
-21.96%
-21.96%
3 Month
-1.34%
-1.34%
6 Month
+17.53%
+17.53%
1 Year
+17.53%
+17.53%

More News

Read More
OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference
From OS Therapies, Inc.
Via Business Wire
OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024
Via InvestorPlace
OS Therapies Announces Closing of $6 Million Private Placement
From OS Therapies, Inc.
Via Business Wire
OS Therapies Partners with B2i Digital to Engage with Biotech Investors Online
From OS Therapies, Inc.
Via Business Wire
OS Therapies Announces Pricing of $6 Million Private Placement
From OS Therapies, Inc.
Via Business Wire
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
From OS Therapies, Inc.
Via Business Wire
OS Therapies to Present at The Spartan Capital Investor Conference
From OS Therapies
Via Business Wire
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
From OS Therapies
Via Business Wire
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
From OS Therapies
Via Business Wire
OS Therapies to Present at the LD Micro Main Event XVII
From OS Therapies
Via Business Wire
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From OS Therapies
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
From OS Therapies
Via Business Wire
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
From OS Therapies
Via Business Wire
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector
Via News Direct
Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (OSTX, ATNM, CRBP, PBYI)
Via AB Newswire
Transforming Oncology: Stocks to Watch in the Oncology Sector
Via News Direct
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Via ACCESSWIRE
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
From OS Therapies
Via Business Wire
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
From OS Therapies
Via Business Wire
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
From OS Therapies
Via Business Wire
OS Therapies Clarifies CUSIP of Common Stock
From OS Therapies
Via Business Wire
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
From OS Therapies
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.